150 related articles for article (PubMed ID: 21278560)
1. Phase II trial of pegylated liposomal doxorubicin in combination with gemcitabine in metastatic breast cancer patients.
Jacquin JP; Chargari C; Thorin J; Mille D; Mélis A; Orfeuvre H; Clavreul G; Chaigneau L; Nourissat A; Dumanoir C; Savary J; Merrouche Y; Magné N
Am J Clin Oncol; 2012 Feb; 35(1):18-21. PubMed ID: 21278560
[TBL] [Abstract][Full Text] [Related]
2. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
Rivera E; Valero V; Arun B; Royce M; Adinin R; Hoelzer K; Walters R; Wade JL; Pusztai L; Hortobagyi GN
J Clin Oncol; 2003 Sep; 21(17):3249-54. PubMed ID: 12947059
[TBL] [Abstract][Full Text] [Related]
4. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience.
Martin-Romano P; Baraibar I; Espinós J; Legaspi J; López-Picazo JM; Aramendía JM; Fernández OA; Santisteban M
Breast J; 2018 Jul; 24(4):473-479. PubMed ID: 29286192
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer.
Wong ZW; Ang PC; Chowbay B; Wong NS; See HT; Khoo KS
Breast; 2008 Oct; 17(5):517-22. PubMed ID: 18502128
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer.
Ulrich-Pur H; Kornek GV; Haider K; Kwasny W; Payrits T; Dworan N; Vormittag L; Depisch D; Lang F; Scheithauer W
Acta Oncol; 2007; 46(2):208-13. PubMed ID: 17453371
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
[TBL] [Abstract][Full Text] [Related]
9. Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study.
Adamo V; Lorusso V; Rossello R; Adamo B; Ferraro G; Lorusso D; Condemi G; Priolo D; Di Lullo L; Paglia A; Pisconti S; Scambia G; Ferrandina G
Br J Cancer; 2008 Jun; 98(12):1916-21. PubMed ID: 18493232
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
Fabi A; Ferretti G; Papaldo P; Salesi N; Ciccarese M; Lorusso V; Carlini P; Carpino A; Mottolese M; Cianciulli AM; Giannarelli D; Sperduti I; Felici A; Cognetti F
Cancer Chemother Pharmacol; 2006 May; 57(5):615-23. PubMed ID: 16163541
[TBL] [Abstract][Full Text] [Related]
11. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Tas F; Guney N; Derin D; Aydiner A; Topuz E
Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
Smorenburg CH; de Groot SM; van Leeuwen-Stok AE; Hamaker ME; Wymenga AN; de Graaf H; de Jongh FE; Braun JJ; Los M; Maartense E; van Tinteren H; Nortier JWR; Seynaeve C
Ann Oncol; 2014 Mar; 25(3):599-605. PubMed ID: 24504445
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
Pectasides D; Pectasides E; Papaxoinis G; Psyrri A; Pliarchopoulou K; Koumarianou A; Macheras A; Athanasas G; Xiros N; Economopoulos T
Gynecol Oncol; 2010 Jul; 118(1):52-7. PubMed ID: 20406710
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.
Rivera E; Valero V; Syrewicz L; Rahman Z; Esteva FJ; Theriault RL; Rosales MM; Booser D; Murray JL; Bast RC; Hortobagyi GN
J Clin Oncol; 2001 Mar; 19(6):1716-22. PubMed ID: 11251001
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
Pectasides D; Xiros N; Papaxoinis G; Aravantinos G; Sykiotis C; Pectasides E; Psyrri A; Koumarianou A; Gaglia A; Gouveris P; Economopoulos T
Gynecol Oncol; 2008 Jan; 108(1):47-52. PubMed ID: 17915300
[TBL] [Abstract][Full Text] [Related]
16. Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial.
Del Barco S; Colomer R; Calvo L; Tusquets I; Adrover E; Sánchez P; Rifà J; De la Haba J; Virizuela JA
Breast Cancer Res Treat; 2009 Jul; 116(2):351-8. PubMed ID: 18941891
[TBL] [Abstract][Full Text] [Related]
17. Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
Poh SB; Bai LY; Chen PM
Am J Clin Oncol; 2005 Dec; 28(6):540-6. PubMed ID: 16317261
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
Mirza MR; Lund B; Lindegaard JC; Keldsen N; Mellemgaard A; Christensen RD; Bertelsen K
Gynecol Oncol; 2010 Oct; 119(1):26-31. PubMed ID: 20638711
[TBL] [Abstract][Full Text] [Related]
19. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
20. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
